Cai D, Xu Y, Ding R, et al. - Since almost 85% of the new patients diagnosed last year with lung cancer are categorized as non-small-cell lung cancer (NSCLC), the recognition of novel diagnostic and prognostic biomarkers to early detect this disease is crucial, and therefore, researchers explored biomarkers in the serum of NSCLC patients. Using a new antibody array methodology, measurements of the expression of 274 cytokines were obtained and the array findings were verified using ELISA. Significantly higher levels of MIP-1 α, IL-8, MIP-1 β, Resistin, GDF-15, HGF, CA125, FLRG, VCAM-1, DKK-3, sTNF-R1, CTACK, Acrp30, CXCL-16 and LYVE-1 were detected in serum samples from NSCLC patients, while lower levels of TIMP-2 and IGFBP-6 were observed. The result of the antibody array was supported by the validation. According to the result of the antibody array, these cytokines might serve as new auxiliary biomarkers for the diagnosis as well as prognosis of NSCLC.